NR4A1 and breast cancer: These studies indicate greater dependence of hormone receptor positive (HR+) breast cancer cells on polyamines for proliferation, which thus suggests that patients with HR+ breast cancer subtype may benefit from therapies that decrease tumour polyamine content.